Analyst firms · Guggenheim · TVTX
Guggenheim TVTX price target and rating history
Travere Therapeutics Inc. (TVTX) · Health Care
Guggenheim rates Travere Therapeutics Inc. (TVTX) Buy with a $25 price target, as of its latest action on Sep 9, 2024. It has published 3 rating actions on TVTX since March 2023, including 1 upgrade and 1 downgrade.
- Current rating
- Buy
- Price target
- $25
- Median target, all firms
- Too few
- Actions on TVTX
- 3
Guggenheim price target on TVTX
Every Guggenheim rating on TVTX
- Sep 9, 2024
- Mar 27, 2024
- Mar 1, 2023
Questions about Guggenheim and TVTX
- What is Guggenheim's price target for TVTX?
- Guggenheim's latest stated price target for Travere Therapeutics Inc. (TVTX) is $25, from its action on Sep 9, 2024.
- What is Guggenheim's rating on TVTX?
- Guggenheim rates TVTX Buy, a bullish rating, as of Sep 9, 2024.
- When did Guggenheim last change its view on TVTX?
- On Sep 9, 2024, Guggenheim upgrades to Buy from Neutral, price target $25.
More TVTX rating histories
All Guggenheim ratingsTVTX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.